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ARTICLE
Clinical Study
Randomised phase 3 study of adjuvant chemotherapy with
or without nadroparin in patients with completely resected
non-small-cell lung cancer: the NVALT-8 study
Harry J. M. Groen1, Erik H. F. M. van der Heijden2, Theo J. Klinkenberg3, Bonne Biesma4, Joachim Aerts5, Ad Verhagen6,
Corinne Kloosterziel7, Remge Pieterman8, Ben van den Borne9, Hans J. M. Smit10, Otto Hoekstra11, Frans M. N. H. Schramel12,
Vincent van der Noort13, Harm van Tinteren13, Egbert F. Smit14 and Anne-Marie C. Dingemans15 for the NVALT Study Group,
the Netherlands
BACKGROUND: Retrospective studies suggest that low molecular weight heparin may delay the development of metastasis in
patients with resected NSCLC.
METHODS: Multicentre phase 3 study with patients with completely resected NSCLC who were randomised after surgery to receive
chemotherapy with or without nadroparin. The main exclusion criteria were R1/2 and wedge/segmental resection. FDG-PET was
required. The primary endpoint was recurrence-free survival (RFS).
RESULTS: Among 235 registered patients, 202 were randomised (nadroparin: n= 100; control n= 102). Slow accrual enabled a
decrease in the number of patients needed from 600 to 202, providing 80% power to compare RFS with 94 events (α= 0.05;
2-sided). There were no differences in bleeding events between the two groups. The median RFS was 65.2 months (95% CI, 36—NA)
in the nadroparin arm and 37.7 months (95% CI, 22.7—NA) in the control arm (HR 0.77 (95% CI, 0.53–1.13, P= 0.19). FDG-PET
SUVmax ≥10 predicted a greater likelihood of recurrence in the first year (HR 0.48, 95% CI 0.22–0.9, P= 0.05).
CONCLUSIONS: Adjuvant nadroparin did not improve RFS in patients with resected NSCLC. In this study, a high SUVmax predicted
a greater likelihood of recurrence in the first year.
CLINICAL TRIAL REGISTRATION: Netherlands Trial registry: NTR1250/1217.
British Journal of Cancer (2019) 121:372–377; https://doi.org/10.1038/s41416-019-0533-3
BACKGROUND
The prognosis of patients with completely resected non-small cell
lung cancer (NSCLC) is mainly determined by stage and
performance status. Adding FDG-PET to CT improves not only
the detection of locoregional and unexpected distant metastasis1,2
but also provides independent survival information based on
tumour metabolic activity.3–5 It may identify patients who are at
increased risk for recurrence and decreased survival and therefore
may benefit from additional treatment.
Adjuvant chemotherapy improves overall survival (OS) in
patients with completely resected NSCLC.6–8 The effect size of
adding chemotherapy is approximately 4% at 5 years. To further
improve survival, the addition of low molecular weight heparin
(LMWH) may be a next step. Three major studies have indicated
that the use of LMWHs may be associated with a survival benefit
in cancer patients that cannot be directly linked to a reduction in
venous thrombotic events (VTEs).9–11 However, not all studies
showed a survival advantage owing to the administration of
LMWH to lung cancer patients.12 ASCO recommendations noted a
lack of sufficient data and therefore stated that anticoagulation
should not be used to extend the survival of patients with cancer
in the absence of other indications.13
We hypothesised that in patients with completely resected
NSCLC with a high risk of recurrence, as defined by high FDG
avidity, adding nadroparin to adjuvant chemotherapy would
improve recurrence-free survival (RFS). To compare standard
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uptake values from PET between different participating centres,
we first initiated a PET quality control programme with phantom
evaluations.
METHODS
This was a prospective multicentre randomised phase 3 study with
patients with completely (R0) resected stage II/III NSCLC,
performance scores of 0–2, adequate organ function, and INRs <1.5
who were eligible for adjuvant chemotherapy (Supplementary
Fig. 1). The exclusion criteria were wedge/segmental resection,
prior chemo- or radiotherapy or contra-indication for nadroparin.
The study was approved by the medical ethics committee of the
University Medical Center Groningen in the Netherlands (METc nr.
2007-076). All patients provided written informed consent.
Patients were randomised at the NVALT Data Center by Alea
randomisation software, and the randomisation results were
communicated via telephone or email; the patients were
randomised after surgery to receive chemotherapy with nadro-
parin subcutaneously daily for 2 weeks at the therapeutic dose
followed by 14 weeks at half the therapeutic dose (for a total of
16 weeks) or chemotherapy alone. Patients received four 3-week
cycles of pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 intrave-
nously. In February 2009, after the enrolment of 11 patients, the
protocol was amended for squamous histology; those patients
received gemcitabine 1250mg/m2 on day 1 and day 8 and
cisplatin 75mg/m2 on day 1 every 3 weeks for 4 cycles. Patients
started adjuvant treatment within 6 weeks after surgery.
Perioperatively, prophylactic LMWH was administered to all
patients until discharge. The stratification factors were institute,
WHO PS (0 or 1 vs. 2), stage, type of resection and previous
malignancy.
The participating centres needed to be able to measure the
standardised uptake value (SUV) in the primary tumour in a
comparable way and, therefore, were obliged to adopt the NedPas
protocol and be accredited by EANM Research Ltd. (EARL).14,15
Patients were registered for the study prior to surgery, and PET
data were centrally analysed before randomisation.
The primary endpoint was RFS, which was measured from the
date of randomisation to the date of first tumour relapse.
The secondary endpoints were OS, dose intensity, quality of
life according to the EORTC QCQ-C30/LC13, toxicity according to
the CTCAE version 3.0, and health economics as measured by the
EuroQol questionnaire.
Assessments
Baseline assessments were performed after surgery with blood
tests, the EuroQol questionnaire and measurements of toxicity. For
staging, the 7th TNM system was used. During chemotherapy,
patients were seen before every cycle. Follow-up was performed
by chest X-ray every 2 months in the first 2 years after surgery and
thereafter every 3 months until 5 years after surgery. Quality of life
was measured at the time of randomisation and 3 weeks after the
end of adjuvant chemotherapy. Health economics were measured
with the EQ5D-3L questionnaire, but the results are not
reported here.
Statistics
Statistical analyses were performed with data from all eligible
patients according to the intention-to-treat principle. It was
estimated that RFS at 3 years after surgery+ adjuvant chemother-
apy would be 60% and that RFS at 3 years after surgery with
adjuvant chemotherapy and nadroparin would be 75%.
Originally, the study was designed as a randomised study with
patients with a high SUVmax measured in the primary tumour
(Supplementary Fig. 1). In January 2010, after 60 patients were
registered, the protocol was adapted due to slow accrual.
SUVmax was not considered a selection criterion, and all
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Fig. 1 Consort diagram for the NVALT-8 study of patients registered in 15 hospitals between December 2007 and July 2013
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resected patients with an indication for adjuvant chemotherapy
were eligible. At that time, 60 patients were enrolled (also
included in the final analysis), and the study was redesigned
as a randomised study, decreasing the number of patients
needed from 600 to 202, which provided 80% power to compare
RFS with 94 events (α= 0.05; 2-sided log-rank test) in both arms
at 3 years ranging from 60 to 75%, assuming exponential
survival over 4 years of follow-up. Cox proportional hazard
models were used to evaluate whether nadroparin was an
independent factor affecting survival after adjustments for age,
PS, stage and SUVmax. The analysis of groups with high and low
SUVmax (cut off 10) values was established as a secondary
endpoint.
Quality of life at 3 weeks after the end of treatment was
assessed with linear models containing as independent variables
the value of the quality of life measure of interest at the baseline,
the treatment arm and an interaction term.
RESULTS
Patients
Between December 2007 and July 2013, 235 patients were
registered before surgery. A total of 202 patients were rando-
mised, and one patient withdrew his informed consent
after surgery prior to randomisation, leaving 99 patients in
the nadroparin arm and 102 patients in the control arm (Fig. 1,
CONSORT). Patient characteristics were similar in the two arms,
except fewer patients had SUVmax values ≥10 in the
nadroparin arm than in the control arm (43 vs 57%, respectively)
(Table 1).
Surgery and adjuvant treatment
The surgical resections were pathologically complete (R0) in 96%
of the patients. Subsequently, 69% of the patients completed 4
cycles of adjuvant chemotherapy (nadroparin arm, 64%; control,
74%). The mean dose intensity for platinum chemotherapy with
and without nadroparin was 92% and 91%, respectively; the
nadroparin dose intensity was 84%. Ninety-nine percent of
patients received full-dose nadroparin for 2 weeks, 92 patients
received the medication during the half-dose period, 2 patients
needed a dose reduction, and 5 patients had poor documentation
of the dosing.
Table 1. Characteristics of 201 randomised patients with resected
NSCLC treated with adjuvant pemetrexed or gemcitabine combined
with platinum with or without nadroparin
CP/CG CP/CG+
nadroparlne
Total
No of patients 102 99 201
Gender (M/F) 63/39 56/43 119 (59%)/
82 (41%)
Age (median+ range) 63 (56–69) 61 (54–67) 62 (54–69)
Performance score
0–1 99 98 197 (98%)
2 3 1 4 (2%)
Histology
Squamous 40 (39%) 36 (36%) 76 (38%)
Non-squamous 62 (61%) 63 (64%) 125 (62%)
TNM stage
pT1N1 32 (31%) 27 (27%) 59 (29%)
pT2N0 6 (6%) 3 (3%) 9 (4%)
pT2N1 24 (24%) 27 (27%) 51 (25%)
pT3N0 17 (17%) 22 (22%) 39 (19%)
pT1-4N0-2 (stage IIIA) 21 (21%) 18 (18%) 39 (19%)
pT1-4N1-3 (stage IIIB) 2 (2%) 2 (2%) 4 (2%)
FDG-PET. O=D
SUVmax <10 20 33 53 (26%)
SUVmax ≥10 75 57 132 (66%)
NEDPAS or EARL not
fulfilled
8 8 16 (8%)
Surgery
(Bi)lobectomy 81 (79%) 77 (78%) 158 (79%)
Pneumonectomy 20 (20 %) 22 (22%) 42 (21%)
Other 1 (1%) 0 (0%) 1 (<1%)
R0 98 (95%) 94 (96%) 192 (96%)
R1 4 (4%) 5 (5%) 9 (4%)
Time from surgery to
start chemo (wk)
5 (5–6) 5 (5–6) 5 (5–6)
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Fig. 2 Recurrence-free survival in patients with resected NSCLC treated with adjuvant chemotherapy with or without nadroparin. CP/CG +N is
cisplatin and pemetrexed/cisplatin and gemcitabine+ nadroparin. HR was 0.77 (95% CI., 0.53–1.13, P= 0.19)
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Toxicity
No differences in toxicities, especially bleeding events, were
observed between the arms, except for grade ≥3 toxicity
neutropenia, which was more common in the nadroparin arm
(20 vs 6 patients, P= 0.002).
Recurrence-free survival
On October 26, 2017, the database was locked after 107 RFS events,
with 48 in the nadroparin arm and 59 in the control arm. The
median follow-up period was 63.1 months (95% CI, 60.5–68.4). The
median RFS was 65.2 months (95% CI, 36—NA) in the nadroparin
arm and 37.7 months (95% CI, 22.7—NA) in the control arm (HR 0.77,
95% CI, 0.53–1.13, P= 0.19) (Fig. 2). The 3-year RFS was 59% (95% CI,
50–70) in the nadroparin arm and 51% (95% CI, 42–62) in the control
arm. After stratification into FDG-based risk groups, the hazard ratio
was 0.70 (95% CI, 0.46–1.04, P= 0.08) (Fig. 3a, b).
Overall survival
Overall survival was not different between the two arms. Overall,
85 patients died; 37 patients in the nadroparin arm died, and 48
patients in the control arm died (HR 0.70 (95% CI., 0.46–1.08), P=
0.10) (Fig. 4). After stratification into FDG-based risk groups, the HR
became 0.67 (95% CI 0.42–1.05, P= 0.08) in the univariate analysis
and 0.75 (95% CI., 0.47–1.2, P= 0.24) in the multivariate analysis.
The 3-year survival rates were 78% (95% CI, 56–75) in the
nadroparin arm and 65% (95% CI, 56–75) in the control arm.
Metabolic tumour activity measured by FDG-PET
The median SUVmax value of the primary tumour in 185 baseline
scans was 13.7, ranging from 9.2 to 18.4; the median values were
not different between the two arms. Eight percent of the scans
(n= 16) did not fulfil the NEDPAS criteria or the centres were not
accredited by EANM Research Ltd. (EARL) (Table 2). Of note, the
phantom calibration of PET scans is part of the EARL accreditation
requirements. The local and central SUVmax measurements were
97% congruent for the cut-off value of 10. In the first year after
randomisation, RFS was inferior for patients with high SUVmax
values (HR 0.48, 95% CI 0.22–0.9, P= 0.05) (Supplementary Fig. 2).
Quality of life
The overall quality of life was not different between the treatment
groups. Quality of life modelling revealed that peripheral
neuropathy and, to a lesser extent, cognitive functioning were
statistically associated with nadroparin treatment after che-
motherapy. This was not the primary outcome, so this observation
should be confirmed in larger studies.
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Fig. 3 a/b Recurrence-free survival in patients with resected NSCLC treated with adjuvant chemotherapy with or without nadroparin stratified
into SUVmax-based risk groups. High risk is defined as SUVmax ≥10 in the primary tumour, while the low risk is defined as SUVmax <10. For
FDG-based risk groups, the HR was 0.70 (95% CI., 0.46–1.04, P= 0.08)
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Fig. 4 Overall survival in patients with resected NSCLC stratified by treatment arm. CP/CG +N is cisplatin and pemetrexed/cisplatin and
gemcitabine+ nadroparin. The HR was 0.70 (95% CI 0.46–1.08, P= 0.10)
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DISCUSSION
Originally, the study was designed to test the hypothesis that in
patients with resected NSCLC and a high risk of recurrence (FDG
SUVmax ≥10), adding nadroparin to adjuvant chemotherapy
would improve their recurrence-free survival. The study accrued
participants slowly and therefore was redesigned. In this study,
adjuvant nadroparin in patients with resected NSCLC undergoing
chemotherapy did not improve RFS (HR 0.77, P= 0.19) after
stratifying for FDG avidity in the primary tumour (HR= 0.70, P=
0.08). No difference in RFS of 15% or larger was observed in this
study; we cannot exclude the possibility of a smaller difference in
RFS. Additionally, the survival curves do not cross throughout their
course. Blocking circulatory tumour cells from invading different
organs with currently available drugs such as bevacizumab or
tinzaparin as adjuvant treatment is not a major method of
improving survival in patients with early-stage NSCLC.16,17 The
reason for our study result may be a lack of power and the
opposing influence of the metabolic correction of SUVmax values
after 1 year, leading to crossing survival curves at 20 months. In
our study, we observed two different patient groups in the high
SUVmax group, one with a very short survival time and one with a
longer survival time (Supplementary Fig. 2).
A recent meta-analysis of the prognostic value of FDG-PET/CT in
surgical NSCLC patients included 36 studies with 5807 patients.18
It was shown that a high SUVmax predicted a higher risk of
recurrence and death and therefore can be used for risk
stratification for disease control and survival. The negative
prognostic role of high FDG uptake remained similar in the
analyses stratified according to stage, pathology and FDG cut-off
values. Our study shows that such a detrimental effect of high
metabolism in the primary tumour disappears after 1 year,
irrespective of nadroparin use.
The different biological functions of LMWH, the impairment of
the occurrence of metastases by the inhibition of tumour cell
growth by heparin-binding growth factors, tumour cell invasion
by heparin-inhibition enzyme systems, tumour cell metastasis by
heparin-binding cell surface selectins, tumour angiogenesis, and
tumour matrix formation were, together with the inconclusive
results from previous studies, the impetus and rationale for
performing this study.19–21 A previous study by Meyer et al.17
examined the effects on survival of tinzaparin and did not find any
benefit for early-stage NSCLC patients. Therefore, low molecular
weight heparins, nadroparin and tinzaparin are not recommended
as adjuvant anti-metastatic agents for patients with early-
stage NSCLC.
In conclusion, adjuvant nadroparin in patients with resected
NSCLC undergoing adjuvant chemotherapy did not improve RFS
even after adjusting for the metabolic activity of the primary
tumour. A high SUVmax value in the primary tumour predicts a
worse recurrence-free survival in resectable NSCLC in the first year
but not thereafter.
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